Join
Live feed
·
PRReleasevia Quantisnow
Sagimet Biosciences Inc. logo

Sagimet Biosciences Advances AURORA U.S. Phase 3 Trial of Denifanstat in Acne Toward Patient Enrollment in Q4 2026

ByQuantisnow·Wall Street's wire, on your screen.
SGMT· Sagimet Biosciences Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track SGMT (Sagimet Biosciences Inc.) and more on Quantisnow.